| abstract |
The present disclosure relates to compositions comprising inhibitors of human complement, and uses of such compositions in methods of treating or preventing complement-associated disorders, among others. In some embodiments, the inhibitor is administered chronically to the patient. In some embodiments, the inhibitor is administered to the patient in an amount and frequency that maintains systemic complement inhibition and prevents breakthrough. In some embodiments, the composition comprises an antibody or antigen-binding fragment thereof that binds human complement component C5 protein or a protein fragment such as C5a or C5b. |